Advanced Enzyme Technologies has reported robust financial performance for the financial year ending March 31, 2026. The company achieved a consolidated net profit of ₹1,736.08 million and declared a final dividend of 67.5%, equivalent to ₹1.35 per equity share. Additionally, the company strengthened its leadership team with key board appointments and finalized the reappointment of its statutory auditors for a second five-year term.
Financial Highlights
For the full financial year ending March 31, 2026, the company reported consolidated revenue from operations of ₹7,457.57 million, compared to ₹6,369.10 million in the previous year. The consolidated net profit for the year reached ₹1,736.08 million, showing significant growth over the ₹1,339.74 million reported in the preceding fiscal year. In the fourth quarter alone, the company generated revenue of ₹2,033.67 million and a net profit of ₹452.52 million.
Dividend and Shareholder Value
Reflecting its healthy financial position and commitment to maximizing long-term value, the Board has recommended a final dividend of 67.5%, or ₹1.35 per equity share (face value of ₹2), subject to approval at the 37th Annual General Meeting. The Board also noted its decision to defer interim dividends to preserve capital for strategic investment opportunities.
Board and Operational Updates
The company has fortified its leadership structure with the re-appointment of Mr. Mukund Madhusudan Kabra as Whole-time Director for a five-year term ending in March 2032. Furthermore, Mr. Pradip Bhailal Shah has been appointed as an Additional Independent Director, effective June 12, 2026. In other governance updates, M S K A & Associates LLP has been reappointed as the company’s statutory auditors until the conclusion of the 42nd Annual General Meeting.
Strategic Growth
The company continues to focus on its core enzyme manufacturing business. During the year, the group expanded its corporate structure by incorporating Advanced Nutrazyme Private Limited. Additionally, the company allotted 49,350 equity shares under its 2022 Employee Stock Options Scheme, further aligning employee interests with the company’s long-term growth objectives.
Source: BSE
